daraxonrasib
AXP000027.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS; NRAS; HRAS
- Originator
- Revolution Medicines
- Sponsor
- Revolution Medicines
Names
Cross-references
- NCI Thesaurus
- C188048
- Wikidata
- Q136659312
- FDA UNII
- B6T47Y2UAP
Approvals
No regulatory approval recorded.
Clinical trials (22)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07898813 | Daraxonrasib in Resectable PDAC | Not yet recruiting | Phase 1 | 2027-04-13 | 2029-02-17 | 30 | Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | Not yet recruiting | Phase 1/2 | 2027-04-09 | 2032-04-09 | 77 | Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Neuroblastoma; Recurrent Childhood Rhabdomyosarcoma; Refractory Childhood Malignant Solid Neoplasm; Refractory Childhood Neuroblastoma; Refractory Childhood Rhabdomyosarcoma |
| NCT07908550 | Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer | Not yet recruiting | Phase 2 | 2027-01 | 2029-12 | 55 | Biliary Tract Cancer (BTC) |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Not yet recruiting | Phase 2 | 2026-11 | 2030-11 | 55 | Ampulla of Vater Carcinoma; Ampullary Carcinoma; Biliary Tract Cancers; Extrahepatic Cholangiocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma (Icc) |
| NCT07895498 | A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | Recruiting | Phase 2 | 2026-10-16 | 2028-10-16 | 122 | Pancreatic Cancer; Skin Toxicities |
| NCT07756281 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer | Recruiting | Phase 1 | 2026-09-01 | 2029-06-01 | 40 | Pancreatic Acinar Carcinoma; Pancreatic Cancer |
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma | Recruiting | Phase 3 | 2026-08-28 | 2029-03 | 400 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07492680 | A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | Recruiting | Phase 2 | 2026-07-27 | 2028-08-15 | 254 | Solid Tumors |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | Phase 3 | 2026-03-09 | 2028-06 | 900 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Recruiting | Phase 1/2 | 2026-01-30 | 2029-05 | 370 | Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Metastatic Solid Tumors; NSCLC; Non-small Cell Lung Cancer (NSCLC) |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Recruiting | Phase 1 | 2026-01-08 | 2028-04 | 574 | Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Lung Cancer (NSCLC); NSCLC; Non-small Cell Lung Cancer (NSCLC); PDAC; Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Phase 3 | 2025-12-15 | 2029-05-10 | 500 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Resectable Pancreatic Ductal Adenocarcinoma (PDAC); Resected Pancreatic Adenocarcinoma |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Recruiting | Phase 1/2 | 2025-05-31 | 2027-06 | 183 | Lung Cancer; MTAP Deletion; NSCLC; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; RAS Mutation; Thoracic Cancer |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Recruiting | Phase 3 | 2025-05-06 | 2027-12-01 | 590 | NSCLC; NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma); Non-Small Cell Lung Cancer |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Active not recruiting | Phase 3 | 2024-10-16 | 2026-06 | 500 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Active not recruiting | Phase 1 | 2024-05-29 | 2026-10-31 | 120 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | Phase 1/2 | 2024-05-24 | 2028-09-30 | 1130 | CRC; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; PDAC; Pancreatic Ductal Adenocarcinoma |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Recruiting | Phase 1/2 | 2024-01-18 | 2027-06 | 616 | KRAS G12C-mutated Solid Tumors, Lung Cancer; KRAS, NRAS, HRAS-mutated NSCLC; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; Non-Small Cell Lung Cancer, NSCLC; RAS G12D-mutated NSCLC |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Recruiting | Phase 1/2 | 2023-11-14 | 2028-12 | 534 | Colorectal Cancer; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Recruiting | Phase 1 | 2023-09-07 | 2026-12-31 | 604 | Advanced Solid Tumors; Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Recruiting | Phase 1/2 | 2022-05-31 | 2027-05-31 | 754 | Advanced Solid Tumors; Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | Approved for marketing | Metastatic Pancreas Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic |
Recent changes
| Seen | Trial | Change | Detail | Title |
|---|---|---|---|---|
| 2026-11-12 | NCT07895498 | new trial | A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | |
| 2026-11-12 | NCT07898813 | new trial | Daraxonrasib in Resectable PDAC | |
| 2026-11-12 | NCT07908550 | new trial | Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer |
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42090791 | Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. | The New England journal of medicine | 2026 | cited by trial NCT05379985 |
| PMID 42169926 | Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report. | Journal of gastrointestinal oncology | 2026 | name in abstract: RMC-6236 |
| PMID 42223072 | Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. | The New England journal of medicine | 2026 | cited by trial NCT06625320 |
| PMID 42244177 | Dermatologic Toxicities Associated With Novel Pan-RAS/RAF Inhibitors. | Journal of cutaneous pathology | 2026 | name in abstract: RMC-6236 |
| PMID 42581230 | Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. | Nature medicine | 2026 | name in title: daraxonrasib |
| PMID 42685317 | Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. | The New England journal of medicine | 2026 | cited by trial NCT05379985 |
| PMID 42827491 | Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report. | Frontiers in immunology | 2026 | name in abstract: daraxonrasib |
| PMID 42955042 | Severe Hypercoagulability With Nonbacterial Thrombotic Endocarditis After KRAS Inhibitor Exposure: A Perfect Storm. | JACC. Case reports | 2026 | name in abstract: daraxonrasib |
| PMID 40056080 | Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. | Journal of medicinal chemistry | 2025 | cited by trial NCT06040541 |
| PMID 40705880 | A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. | Science (New York, N.Y.) | 2025 | cited by trial NCT06040541 |
| PMID 38589574 | Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. | Nature | 2024 | cited by trial NCT05379985 |
| PMID 38593348 | Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. | Cancer discovery | 2024 | cited by trial NCT05379985 |
| PMID 37590355 | Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. | Science (New York, N.Y.) | 2023 | cited by trial NCT05379985 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41186497 | RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. | Cancer immunology research | 2026 | name in abstract: daraxonrasib |
| PMID 41519889 | Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors. | Nature communications | 2026 | name in abstract: RMC-6236 |
| PMID 41543339 | RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2026 | name in title: RMC-6236 |
| PMID 41576808 | Insights into RAS-driven melanoma and its therapeutic implications. | Cancer treatment reviews | 2026 | name in abstract: daraxonrasib |
| PMID 41661652 | The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition. | Cancer research | 2026 | name in abstract: RMC-6236 |
| PMID 41663526 | Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases. | Cancer gene therapy | 2026 | name in abstract: RMC-6236 |
| PMID 41670434 | Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. | Cancer discovery | 2026 | name in abstract: daraxonrasib |
| PMID 41756246 | AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids. | Frontiers in pharmacology | 2026 | name in abstract: RMC-6236 |
| PMID 41756844 | Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma. | bioRxiv : the preprint server for biology | 2026 | name in title: daraxonrasib |
| PMID 41959066 | Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance. | bioRxiv : the preprint server for biology | 2026 | name in abstract: RMC-6236 |
| PMID 41969644 | Acral Lentiginous Melanoma With NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational KRASG12C Inhibitor: Case Report. | Case reports in oncological medicine | 2026 | name in abstract: RMC-6236 |
| PMID 41993359 | KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. | bioRxiv : the preprint server for biology | 2026 | name in abstract: RMC-6236 |
| PMID 42030031 | GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition. | Biological chemistry | 2026 | name in title: daraxonrasib |
| PMID 42030930 | Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. | Cancer cell | 2026 | name in abstract: daraxonrasib |
| PMID 42031346 | From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC. | Critical reviews in oncology/hematology | 2026 | name in abstract: RMC-6236 |
| PMID 42092352 | Disrupted molecular glue complex drives RAS inhibitor resistance. | Cell | 2026 | name in abstract: daraxonrasib |
| PMID 42094384 | Macrophage-Derived PDGF-BB and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer. | bioRxiv : the preprint server for biology | 2026 | name in abstract: RMC-6236 |
| PMID 42107507 | Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue. | Pharmacological research | 2026 | name in title: daraxonrasib |
| PMID 42135489 | Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer. | Nature reviews. Clinical oncology | 2026 | name in title: daraxonrasib |
| PMID 42171647 | Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma. | Cancer research | 2026 | name in abstract: daraxonrasib |
| PMID 42224594 | A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. | Proceedings of the National Academy of Sciences of the United States of America | 2026 | name in abstract: daraxonrasib |
| PMID 42225610 | Skin health in oncology: evidence-based skin care for cancer patients. | The oncologist | 2026 | name in abstract: daraxonrasib |
| PMID 42279426 | Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance. | Cancers | 2026 | name in abstract: daraxonrasib |
| PMID 42282555 | Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236. | bioRxiv : the preprint server for biology | 2026 | name in title: RMC-6236 |
| PMID 42286127 | Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma. | Nature reviews. Clinical oncology | 2026 | name in title: daraxonrasib |
| PMID 42286311 | Positive results for daraxonrasib for previously treated metastatic pancreatic cancer. | Nature reviews. Gastroenterology & hepatology | 2026 | name in title: daraxonrasib |
| PMID 42372907 | The potential role of daraxonrasib (RMC-6236) in relapsed neuroblastoma patients and the urgent need for preclinical investigations. | Journal of pediatric surgery | 2026 | name in title: daraxonrasib |
| PMID 42393724 | KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. | Journal of hematology & oncology | 2026 | name in abstract: RMC-6236 |
| PMID 42398486 | In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer. | Journal of molecular graphics & modelling | 2026 | name in abstract: daraxonrasib |
| PMID 42415848 | M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS. | bioRxiv : the preprint server for biology | 2026 | name in title: daraxonrasib |
| PMID 42433800 | Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier? | Annals of medicine and surgery (2012) | 2026 | name in title: daraxonrasib |
| PMID 42433811 | From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial - a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants? | Annals of medicine and surgery (2012) | 2026 | name in title: daraxonrasib |
| PMID 42436354 | CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC. | The EMBO journal | 2026 | name in title: daraxonrasib |
| PMID 42457978 | Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators. | Acta pharmacologica Sinica | 2026 | name in abstract: RMC-6236 |
| PMID 42465401 | Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer. | bioRxiv : the preprint server for biology | 2026 | name in title: daraxonrasib |
| PMID 42485639 | Daraxonrasib in Advanced RAS-Mutated Pancreatic Cancer. | The New England journal of medicine | 2026 | name in title: daraxonrasib |
| PMID 42485640 | Daraxonrasib in Advanced RAS-Mutated Pancreatic Cancer. Reply. | The New England journal of medicine | 2026 | name in title: daraxonrasib |
| PMID 42523398 | Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment. | bioRxiv : the preprint server for biology | 2026 | name in abstract: daraxonrasib |
| PMID 42551924 | [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: daraxonrasib |
| PMID 42551925 | [Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: daraxonrasib |
| PMID 42557936 | Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies. | Cancer science | 2026 | name in title: daraxonrasib |
| PMID 42562950 | RAF1 S257L/S259F hotspot mutations: functional characterization and intrinsic resistance to the RAS(ON) inhibitor daraxonrasib in melanoma. | Oncogene | 2026 | name in title: daraxonrasib |
| PMID 42567220 | Daraxonrasib in pancreatic cancer: When progress disrupts practice. | Drug discovery today | 2026 | name in title: daraxonrasib |
| PMID 42571010 | The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. | Journal of hematology & oncology | 2026 | name in abstract: daraxonrasib |
| PMID 42580397 | The Allosteric Revolution: From Static Structures to Conformational Ensembles and Next-Generation Therapeutics. | Journal of molecular biology | 2026 | name in abstract: daraxonrasib |
| PMID 42600570 | Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind? | Med (New York, N.Y.) | 2026 | name in title: daraxonrasib |
| PMID 42610483 | Daraxonrasib doubles survival in patients with metastatic pancreatic cancer. | Cancer | 2026 | name in title: daraxonrasib |
| PMID 42612796 | Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer. | Annals of oncology : official journal of the European Society for Medical Oncology | 2026 | name in abstract: daraxonrasib |
| PMID 42615854 | Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies. | Future medicinal chemistry | 2026 | name in abstract: RMC-6236 |
| PMID 42617733 | ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer. | Annals of oncology : official journal of the European Society for Medical Oncology | 2026 | name in title: daraxonrasib |
| PMID 42619397 | Daraxonrasib significantly improves overall and progression-free survival in patients with previously treated metastatic pancreatic cancer. | CA: a cancer journal for clinicians | 2026 | name in title: daraxonrasib |
| PMID 42620187 | A Compact, Standalone & Battery-Powered 3D Organoid-on-Chip System with Programmable Flow Control. | bioRxiv : the preprint server for biology | 2026 | name in abstract: daraxonrasib |
| PMID 42620265 | Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma. | bioRxiv : the preprint server for biology | 2026 | name in abstract: daraxonrasib |
| PMID 42645357 | Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: daraxonrasib |
| PMID 42649211 | Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. | Nature communications | 2026 | name in title: daraxonrasib |
| PMID 42658041 | Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. | Cancer research | 2026 | name in title: daraxonrasib |
| PMID 42663603 | The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror? | Future oncology (London, England) | 2026 | name in abstract: daraxonrasib |
| PMID 42667948 | XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. | Cancer letters | 2026 | name in abstract: daraxonrasib |
| PMID 42674713 | Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. | Anticancer research | 2026 | name in title: daraxonrasib |
| PMID 42678463 | Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. | Journal of gastrointestinal cancer | 2026 | name in abstract: daraxonrasib |
| PMID 42679154 | Discovery and Characterization of RP04340: A Highly Potent and Orally Active Pan-KRAS PROTAC Degrader. | Journal of medicinal chemistry | 2026 | name in abstract: RMC-6236 |
| PMID 42683315 | The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition. | Frontiers in molecular neuroscience | 2026 | name in abstract: daraxonrasib |
| PMID 42689323 | Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer. | Cancer discovery | 2026 | name in abstract: daraxonrasib |
| PMID 42691452 | Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | name in title: daraxonrasib |
| PMID 42694779 | Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma. | Cureus | 2026 | name in title: daraxonrasib |
| PMID 42705602 | Equity in expanded access programs for daraxonrasib. | Journal of cancer policy | 2026 | name in title: daraxonrasib |
| PMID 42720810 | Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: RMC-6236 |
| PMID 42731942 | [In patients with previously treated metastatic pancreatic adenocarcinoma, does daraxonrasib improve overall survival and progression-free survival compared with standard chemotherapy, while being safe?]. | La Revue de medecine interne | 2026 | name in title: daraxonrasib |
| PMID 42746687 | ctDNA Profiling Identifies Daraxonrasib Resistance Mechanisms. | Cancer discovery | 2026 | name in title: daraxonrasib |
| PMID 42749837 | Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC. | Nature reviews. Clinical oncology | 2026 | name in title: daraxonrasib |
| PMID 42750735 | RAS-targeted therapies for pancreatic cancer. | ESMO gastrointestinal oncology | 2026 | name in abstract: daraxonrasib |
| PMID 42752392 | Daraxonrasib (Rasonque) for metastatic pancreatic cancer. | The Medical letter on drugs and therapeutics | 2026 | name in title: daraxonrasib |
| PMID 42759542 | Targeting KRAS-Mutant Lung Cancers. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: daraxonrasib |
| PMID 42776617 | Current landscape of RAS-targeted therapy for pancreatic cancer. | The oncologist | 2026 | name in abstract: daraxonrasib |
| PMID 42778216 | Daraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK? | BMJ (Clinical research ed.) | 2026 | name in title: daraxonrasib |
| PMID 42779967 | Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition. | bioRxiv : the preprint server for biology | 2026 | name in title: daraxonrasib |
| PMID 42797417 | Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach. | Pharmaceuticals (Basel, Switzerland) | 2026 | name in abstract: daraxonrasib |
| PMID 42802048 | Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma. | Drug discoveries & therapeutics | 2026 | name in title: daraxonrasib |
| PMID 42803106 | Q&A: Eileen O'Reilly on Pancreatic Cancer. | Cancer discovery | 2026 | name in abstract: daraxonrasib |
| PMID 42804710 | Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer. | Expert opinion on biological therapy | 2026 | name in abstract: daraxonrasib |
| PMID 42806361 | Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes. | Experimental hematology & oncology | 2026 | name in title: daraxonrasib |
| PMID 42814859 | Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. | Cancer research | 2026 | name in title: daraxonrasib |
| PMID 42825474 | Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor Resistance. | Cancer research | 2026 | name in abstract: RMC-6236 |
| PMID 42829436 | Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma. | Experimental hematology & oncology | 2026 | name in title: RMC-6236 |
| PMID 42836673 | Targeting RAS in pancreatic cancer. | Cancer | 2026 | name in abstract: daraxonrasib |
| PMID 42836735 | Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2026 | name in abstract: daraxonrasib |
| PMID 42841489 | Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: daraxonrasib |
| PMID 42860233 | Blockade of mutant RAS oncogenic signaling: A 2026 update. | Pharmacological research | 2026 | name in abstract: daraxonrasib |
| PMID 42863589 | Opioid Selection on Daraxonrasib: P-Glycoprotein (P-gp) Blockade and Opioid. | Journal of pain and symptom management | 2026 | name in title: daraxonrasib |
| PMID 42869992 | An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval. | Nature reviews. Clinical oncology | 2026 | name in title: daraxonrasib |
| PMID 42870846 | Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines. | Translational lung cancer research | 2026 | name in abstract: daraxonrasib |
| PMID 42882807 | Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review. | Cancers | 2026 | name in title: daraxonrasib |
| PMID 42906096 | Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. | The New England journal of medicine | 2026 | name in title: daraxonrasib |
| PMID 42906097 | Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. | The New England journal of medicine | 2026 | name in title: daraxonrasib |
| PMID 42919442 | Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design. | Experimental hematology & oncology | 2026 | name in abstract: daraxonrasib |
| PMID 42946971 | Development and Validation of an UPLC-QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan-KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies. | Biomedical chromatography : BMC | 2026 | name in title: daraxonrasib |
| PMID 42954967 | The Price of Hope-A Brazilian Oncologist's 4 Encounters With Daraxonrasib. | JAMA oncology | 2026 | name in title: daraxonrasib |
| PMID 42956271 | Efficacy and Safety of KRAS-Targeted Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: An Updated Systematic Review and Meta-Analysis of Pooled Proportions. | American journal of clinical oncology | 2026 | name in abstract: daraxonrasib |
| PMID 42956743 | KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. | Cancer cell | 2026 | name in abstract: RMC-6236 |
| PMID 42962509 | Beyond RAS G12 grouping: testing treatment-specific prediction after daraxonrasib in pancreatic cancer. | Cancer treatment and research communications | 2026 | name in title: daraxonrasib |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| F31CA318096 | Elucidation and targeting of RAS inhibitor induced metabolic reprogramming for the treatment of pancreatic cancer | UNIV OF NORTH CAROLINA CHAPEL HILL | ACKERMANN, SARAH | 2026–2026 | name in abstract: daraxonrasib |
| R01CA176839 | Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma Therapy | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH | MCMAHON, MARTIN | 2026–2026 | name in project terms: daraxonrasib |
| R01CA190394 | Targeting the cytokine circuitry of KRAS driven lung cancer | DANA-FARBER CANCER INST | BARBIE, DAVID A | 2026–2026 | name in project terms: daraxonrasib |
| R01CA300785 | Adaptation and Evolution of Resistance to Pan-RAS inhibition in PDAC | COLUMBIA UNIVERSITY HEALTH SCIENCES | OLIVE, KENNETH P. | 2026–2026 | name in abstract: RMC-6236 |
| R01CA316420 | Advancing Pan-RAS Inhibitors for Colorectal Cancer Interception: A Dual Approach Integrating Natural Product Drug Discovery and Preclinical Development | AUBURN UNIVERSITY AT AUBURN | PIAZZA, GARY A | 2026–2026 | name in abstract: daraxonrasib |
| R21CA309360 | Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancer | UNIV OF NORTH CAROLINA CHAPEL HILL | MILNER, JOHN JUSTIN | 2026–2026 | name in abstract: RMC-6236 |
| UG3CA311486 | Novel pan-RAS Inhibitors from Natural Products: A Safer Approach for Colorectal Cancer Interception | AUBURN UNIVERSITY AT AUBURN | PIAZZA, GARY A | 2026–2026 | name in project terms: daraxonrasib |
| R21CA297690 | Noncovalent interaction of mutant KRAS inhibitors | DUKE UNIVERSITY | CHI, JEN-TSAN ASHLEY | 2025–2025 | name in abstract: RMC-6236 |
Notes
Multi-selective RAS(ON) tri-complex inhibitor. FDA approved 2026-08-26 as Rasonque (pancreatic cancer).
How to cite
daraxonrasib (AXP000027.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000027.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.